Technical Analysis for LCTX - Lineage Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
C 2.26 4.15% 0.09
LCTX closed up 4.15 percent on Friday, May 14, 2021, on 59 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical LCTX trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Earnings Movers Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish 4.15%
MACD Bearish Centerline Cross Bearish 4.15%
Expansion Pivot Sell Setup Bearish Swing Setup 4.15%
Stochastic Reached Oversold Weakness 4.15%
Earnings Movers Other 4.15%
Older End-of-Day Signals for LCTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day 3 days ago
Possible NR7 3 days ago
Up 10% 3 days ago
Up 1 ATR 3 days ago
Gapped Up (Partial) 3 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Lineage Cell Therapeutics, Inc. Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Clinical Development Immunotherapy Bone Cancer Immunotherapy Stem Cells Small Cell Lung Cancer Non Small Cell Lung Cancer Macular Degeneration Drug Delivery Related Macular Degeneration Cell Therapy Degenerative Disease Osteoarthritis Degenerative Diseases Retina Injuries Human Disease Aesthetics Spinal Cord Pivotal Progenitor Cell Starch Bone Grafting Dendritic Cell Helium EMV Stem Cell Therapy Biotime Dry Age Related Macular Degeneration Treatment Of Degenerative Diseases

Is LCTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.13
52 Week Low 0.7299
Average Volume 1,226,069
200-Day Moving Average 1.76
50-Day Moving Average 2.41
20-Day Moving Average 2.52
10-Day Moving Average 2.52
Average True Range 0.21
ADX 15.22
+DI 15.30
-DI 26.45
Chandelier Exit (Long, 3 ATRs ) 2.26
Chandelier Exit (Short, 3 ATRs ) 2.79
Upper Bollinger Band 2.93
Lower Bollinger Band 2.11
Percent B (%b) 0.18
BandWidth 32.39
MACD Line -0.02
MACD Signal Line 0.03
MACD Histogram -0.0577
Fundamentals Value
Market Cap 338.98 Million
Num Shares 150 Million
EPS 0.23
Price-to-Earnings (P/E) Ratio 9.74
Price-to-Sales 85.10
Price-to-Book 2.53
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.53
Resistance 3 (R3) 2.54 2.47 2.49
Resistance 2 (R2) 2.47 2.40 2.46 2.47
Resistance 1 (R1) 2.36 2.36 2.33 2.35 2.45
Pivot Point 2.29 2.29 2.27 2.28 2.29
Support 1 (S1) 2.18 2.22 2.15 2.17 2.07
Support 2 (S2) 2.11 2.18 2.10 2.05
Support 3 (S3) 2.00 2.11 2.04
Support 4 (S4) 1.99